论文部分内容阅读
Objective To observe the efficiency and safety of Thymosin-al for treatment of anti-HBe- and HBV DNA-positive chronic hepatitis B. Methods 56 patients were randomly divided into group A and B, and the baseline were comparable between group A and B (P>0